Hear from the experts on the optimal use of targeted therapy for metastatic colorectal cancer (mCRC). Practical challenges like treatment sequence, third-line therapy and management of high microsatellite instability (MSI-H) will be discussed based on clinical scenarios with patient history, laboratory results, and options for next steps in treatment to provide commentary and insight for decision making in the care of your patients with mCRC.
Oct 31, 2017
Oct 31, 2018
Alberto Sobrero, MDOspedale San Martino
Rui-Hua Xu, MD, PhDSun Yat-sen University Cancer Center
This activity is intended for medical oncologists, gastroenterologists, radiation and surgical oncologists, and other healthcare professionals involved in the management of patients with mCRC.
After successful completion of this educational activity, participants should be able to:
- Describe findings from recent clinical trials that can help determine an appropriate treatment sequence based on individual patient and disease characteristics
- Distinguish the adverse event profiles associated with treatment options for relapsed mCRC, as well as dose adjustment strategies for management of treatment-related complications
- Select an appropriate dose of therapy for patients with mCRC
This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.